GVHD represents a life-threatening complication post stem cell transplantation and allogeneic CAR T cell therapy without effective treatment. It's truly unmet medical needs.
Acute GVHD (aGVHD) is characterized by rapid-onset immune reactions, primarily driven by alloreactive T cells recognizing host tissues as foreign. This process involves tissue damage, inflammatory cytokine release, and subsequent organ dysfunction. The infusion of CAR-T cells can influence the alloreactive response, influencing the severity and onset of acute GVHD in transplant recipients.
A sequential inflammatory cascade participated by cellular networks involves host dendritic cells, donor T cells and effector cells, and B cells.
Chronic graft-versus-host disease (cGVHD) is a significant cause of late mortality following allogeneic hematopoietic stem cell transplantation. Patients with moderate-to-severe cGVHD often experience diminished health-related quality of life and face a considerable disease burden. Currently, corticosteroids, with or without calcineurin inhibitors, are the primary treatment for cGVHD. However, the outlook for patients with steroid-refractory cGVHD (SR-cGVHD) is notably poor. The causes of steroid resistance remain poorly understood, and standardized second-line treatment protocols for SR-cGVHD are lacking.
Chronic Graft-versus-Host Disease significantly impairs quality of life for transplant recipients. Chronic GVHD manifests through complex immune dysregulation, leading to prolonged tissue damage and organ dysfunction. Our research illuminates how CAR-T technology can modulate these immune pathways, offering targeted and effective interventions.
Copyright © 2024 celeontherapeutics.com - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.